Childhood Gastrointestinal Neuroendocrine Tumors
Gastrointestinal Neuroendocrine Tumors in children and adolescents
TREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 26, 2024. Captured 2026-09-09.
Treatment options for neuroendocrine tumors of the appendix include the following:
Appendectomy.
In adults, it has been accepted practice to remove the entire right colon in patients with large neuroendocrine tumors of the appendix (>2 cm in diameter) or with tumors that have spread to the lymph nodes.[5-8]
In children and adolescents, however, study results suggest that appendectomy alone is sufficient treatment for appendiceal neuroendocrine tumors, regardless of size, position, histology, or nodal or mesenteric involvement. Right hemicolectomy is unnecessary in children. Routine follow-up imaging and biological studies are not beneficial.[5,8-10]
Evidence (appendectomy alone):
The Italian Tumori Rari in Etá Pediatrica project performed a prospective registry study that evaluated 113 pediatric patients with appendiceal neuroendocrine tumors.[9][Level of evidence C1] Primary re-excision was not recommended for completely excised tumors smaller than 2 cm, except for microscopic/macroscopic residual tumor on the margins of the appendix. In these cases, cecum resection and pericecal node biopsy was recommended. Decisions about tumors larger than 2 cm were made at the discretion of the primary physicians. However, physicians were discouraged from performing right hemicolectomy unless margins were positive. Of the 113 study participants, 108 had tumors smaller than 2 cm. Thirty-five patients had extension of tumor beyond the appendiceal wall. Five tumors invaded the serosa, and 28 tumors invaded the periappendiceal fat. Margins were clear in 111 of 113 patients. The study concluded that appendectomy alone should be considered curative for most pediatric patients with appendiceal neuroendocrine tumors. The procedure of choice is a resection of the appendix without hemicolectomy.
Sources: 9 · Level of evidence C1
The Italian Tumori Rari in Etá Pediatrica project performed a prospective registry study that evaluated 113 pediatric patients with appendiceal neuroendocrine tumors.[9][Level of evidence C1] Primary re-excision was not recommended for completely excised tumors smaller than 2 cm, except for microscopic/macroscopic residual tumor on the margins of the appendix. In these cases, cecum resection and pericecal node biopsy was recommended. Decisions about tumors larger than 2 cm were made at the discretion of the primary physicians. However, physicians were discouraged from performing right hemicolectomy unless margins were positive. Of the 113 study participants, 108 had tumors smaller than 2 cm. Thirty-five patients had extension of tumor beyond the appendiceal wall. Five tumors invaded the serosa, and 28 tumors invaded the periappendiceal fat. Margins were clear in 111 of 113 patients. The study concluded that appendectomy alone should be considered curative for most pediatric patients with appendiceal neuroendocrine tumors. The procedure of choice is a resection of the appendix without hemicolectomy.
At 41 months of follow-up, all 113 patients were alive.
The five patients with tumors larger than 2 cm did well.
One patient had resection of the cecum; no residual tumor was found.
One patient had a right hemicolectomy (tumor was <2 cm with clear margins, but an octreotide scan was possibly positive), and no tumor was found.
A French multicenter study of children younger than 18 years with neuroendocrine tumors of the appendix was carried out by surveying pediatric surgeons from 1988 to 2012. A total of 114 patients were identified. Risk factors for secondary right hemicolectomy were tumor extension into the mesoappendix, positive margins, size larger than 2 cm, and high proliferative index. Eighteen patients met the above criteria and were observed.[10]The investigator's recommendation was that appendectomy alone is sufficient treatment for neuroendocrine tumors of the appendix.
Sources: 10
A French multicenter study of children younger than 18 years with neuroendocrine tumors of the appendix was carried out by surveying pediatric surgeons from 1988 to 2012. A total of 114 patients were identified. Risk factors for secondary right hemicolectomy were tumor extension into the mesoappendix, positive margins, size larger than 2 cm, and high proliferative index. Eighteen patients met the above criteria and were observed.[10]The investigator's recommendation was that appendectomy alone is sufficient treatment for neuroendocrine tumors of the appendix.
All patients were alive and had no disease at follow-up.
In addition, follow-up radiological studies and biological tests were not helpful.
A systematic review and meta-analysis of 38 studies of appendiceal neuroendocrine tumors identified 958 patients with a mean age at presentation of 11.6 years. Tumor size was 2 cm or smaller in 85% of the cases. Of the 24 papers that reported the status of the resection margin, 97% of tumors had negative margins. Nodal involvement was reported in ten series and was present in 1.4% of cases, with higher rates seen in patients whose tumors were larger than 2 cm (35%). Vascular involvement was seen in 11% of 510 patients, and invasion of the mesoappendix or periappendiceal fat was reported in 29% of 910 patients.[8]
Sources: 8
A systematic review and meta-analysis of 38 studies of appendiceal neuroendocrine tumors identified 958 patients with a mean age at presentation of 11.6 years. Tumor size was 2 cm or smaller in 85% of the cases. Of the 24 papers that reported the status of the resection margin, 97% of tumors had negative margins. Nodal involvement was reported in ten series and was present in 1.4% of cases, with higher rates seen in patients whose tumors were larger than 2 cm (35%). Vascular involvement was seen in 11% of 510 patients, and invasion of the mesoappendix or periappendiceal fat was reported in 29% of 910 patients.[8]
According to the European and American Neuroendocrine Tumor Societies, 189 patients met the criteria for a secondary procedure after initial appendectomy, but only 69 patients underwent a secondary procedure (n = 43, hemicolectomy; n = 2, ileocecectomy; n = 1, cecectomy; n = 2, ileocolectomy; n = 21, not specified).
Of the 120 patients who did not have a secondary procedure, 91 patients had tumors extending to the mesoappendix, 5 patients had vascular invasion, 4 patients had positive margins, 12 patients had tumors 2 cm or larger, 1 patient had a high proliferative index, and 7 patients had positive lymph nodes.
No disease recurrences were reported in patients who had a secondary procedure or in those who were observed.
Preoperative and postoperative imaging was not helpful in managing patients.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 26, 2024. Captured 2026-09-09.
Complete surgical resection and localized disease are associated with a favorable clinical outcome.[2,7]
In one retrospective single-institution study, the 5-year relapse-free survival rate was 41% for patients with extra-appendiceal neuroendocrine tumors. The overall survival (OS) rate was 66%.[3]
Sources: 3
Treatment options for resectable extra-appendiceal neuroendocrine tumors include the following:
Surgery.[8]
Sources: 8
Treatment options for unresectable or multifocal extra-appendiceal neuroendocrine tumors include the following:
Embolization.[9]
Sources: 9
Peptide receptor radionuclide therapy.[12]
Sources: 12
Mammalian target of rapamycin (mTOR) inhibitors.[13]
Sources: 13
Tyrosine kinase inhibitors (TKIs).[14]
Sources: 14
Immunotherapies.[15]
Sources: 15
SSTR2 ligands include octreotide, long-acting repeatable octreotide, and lanreotide. Octreotide is not practical for therapy because its short half-life necessitates frequent administration. Long-acting, repeatable octreotide and lanreotide have been evaluated in prospective, randomized, placebo-controlled trials.[10,11] Patient age was not specified in the first trial, and eligibility was restricted to age 18 years and older in the second trial. Neither agent produced significant objective responses in measurable tumors. Both agents were associated with statistically significant increases in progression-free survival and time to progression, and both agents are recommended for the treatment of unresectable extra-appendiceal neuroendocrine tumors in adults.
A phase III trial included 231 patients with advanced or metastatic extra-appendiceal neuroendocrine tumors. Patients were randomly assigned to treatment with lutetium Lu 177 (177Lu)-DOTATATE plus long-acting octreotide or high-dose long-acting octreotide (control group). While the median OS did not reach statistical significance, there was an 11.7-month difference, with 48.0 months (95% confidence interval [CI], 37.4–55.2) in the 177Lu-DOTATATE group and 36.3 months (95% CI, 25.9–51.7) in the control group.[16] The U.S. Food and Drug Administration approved the use of 177Lu-DOTATATE for children aged 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.
Sources: 16
Embolization, peptide receptor radionuclide therapy, mTOR inhibitors, and TKIs have been used for treatment.[9,12-14]
Conventional cytotoxic chemotherapy appears to be inactive.[3]
Sources: 3
Source: Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 26, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 26, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer, such as Gastrointestinal Neuroendocrine Tumors Treatment.
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of gastrointestinal neuroendocrine tumor. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with cancer and who specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
pediatric surgeon
Sources: pediatric surgeon
pathologist
Sources: pathologist
pediatric endocrinologist
Sources: endocrinologist
pediatric nurse specialist
Sources: pediatric nurse specialist
social worker
Sources: social worker
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
child-life specialist
Sources: child-life specialist
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
There are different types of treatment for children and adolescents with a gastrointestinal neuroendocrine tumor. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.
Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Types of treatment your child might have include:
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Surgery to remove the tumor is the only treatment needed for neuroendocrine tumor in the appendix. Surgery is also used alone or with other therapies to treat neuroendocrine tumors outside the appendix.
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Embolization is a treatment in which contrast dye and particles are injected into the hepatic artery through a catheter (thin tube). The particles block the artery, cutting off blood flow to the tumor. Sometimes a small amount of a radioactive substance is attached to the particles. Most of the radiation is trapped near the tumor to kill the cancer cells. This is called radioembolization.
Sources: contrast dye · injected · hepatic artery · artery · radiation
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
A radioactive drug contains a radioactive substance and is used to diagnose or treat disease, including cancer. Lutetium Lu 177-dotatate is a radioactive drug used to treat gastrointestinal neuroendocrine tumor.
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Treatment of neuroendocrine tumor in the appendix in children is surgery to remove the appendix.
Treatment of neuroendocrine tumor in the large intestine, pancreas, or stomach is usually surgery.
Treatment of neuroendocrine tumor that cannot be removed by surgery, multiple tumors, or tumors that have spread may include:
embolization
radioactive drug (lutetium Lu 177-dotatate)
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Source: Childhood Gastrointestinal Neuroendocrine Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:
physical problems
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer) or other problems
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.
Gastrointestinal Neuroendocrine Tumors in children and adolescents